In re: MDL 2700 Genentech, Inc. Herceptin (Traztuzumab) Marketing and Sales Litigation

U.S. Court of Appeals for the Tenth Circuit

Tab Group

Merits Stage

Tenth Circuit reverses district court’s summary-judgment ruling for Genentech, rejecting the district court’s conclusion that federal law preempts plaintiffs’ state-law claims

May 29, 2020

Click here to view the opinion. The U.S. Chamber filed a brief urging the court to affirm the district court’s ruling.

U.S. Chamber urges Tenth Circuit to hold that federal law preempts state-law claims challenging statements on a prescription drug’s label concerning the amount of the drug included in a vial

October 11, 2019

Click here to view the Chamber’s amicus brief.

Jeremy M. Bylund, Jeffrey S. Bucholtz, Marisa C. Maleck, and Gabriel Krim of King & Spalding LLP served as co-counsel for the U.S. Chamber of Commerce on behalf of the U.S. Chamber Litigation Center.

Case Documents

Appellants' Opening Brief (Redacted) -- In re MDL 2700 Genentech, Inc. Herceptin (Traztuzumab) Marketing and Sales Litigation (Tenth Circuit).pdf

U.S. Chamber Amicus Brief -- In re MDL 2700 Genentech, Inc. Herceptin (Traztuzumab) Marketing and Sales Litigation (Tenth Circuit).pdf

Opinion -- In re MDL 2700 Genentech, Inc. Herceptin (Traztuzumab) Marketing and Sales Litigation (Tenth Circuit).pdf